State Street’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

State Street’s Portfolio TLIS Stock Details TLIS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-3,162	Closed	-$22.8K	–	4619
2023 Q2	$22.8K	Sell	3,162 -140	-4%	-$1.02K	﹤0.01%	4579
2023 Q1	$24.3K	Hold	3,302	–	–	﹤0.01%	4652
2022 Q4	$22K	Hold	3,302	–	–	﹤0.01%	4717
2022 Q3	$34K	Sell	3,302 -64	-2%	-$809	﹤0.01%	4741
2022 Q2	$41K	Sell	3,366 -13,408	-80%	-$212K	﹤0.01%	4761
2022 Q1	$355K	Sell	16,774 -980	-6%	-$33.9K	﹤0.01%	4180
2021 Q4	$1.07M	Buy	17,754 +1,848	+12%	+$138K	﹤0.01%	3801
2021 Q3	$1.49M	Buy	15,906 +2,178	+16%	+$290K	﹤0.01%	3694
2021 Q2	$2.27M	Buy	13,728 +3,924	+40%	+$667K	﹤0.01%	3524
2021 Q1	$1.89M	Buy	+9,804	New	+$2.45M	﹤0.01%	3462

Other funds holding TLIS

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

State Street's TLIS Position: Q3 2023 in Review

State Street sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q3 2023, closing a stake of 3,162 shares — an estimated $22.8K sold.

State Street first reported a position in TLIS in Q1 2021 and held it in 10 quarters. The position peaked at $2.27M in Q2 2021. 19 funds tracked by Wall St. Rank hold TLIS as of Q3 2023.

State Street reported no remaining Talis Biomedical Corporation Common Stock position as of Q3 2023 after selling out during the quarter.
State Street sold 3,162 Talis Biomedical Corporation Common Stock shares in Q3 2023, an estimated $22.8K.
State Street first reported a position in Talis Biomedical Corporation Common Stock in Q1 2021 and held it in 10 quarters.
State Street's Talis Biomedical Corporation Common Stock position peaked at $2.27M in Q2 2021.
19 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q3 2023.

Based on State Street's 13F filing for Q3 2023, filed 14 Nov 2023.